Embecta (EMBC) Stock: Buy, Sell, or Hold?
EMBC - Embecta Corp. Common Stock
$6.79
0.11 (1.65%)
▲
5d:
+5.27%
30d:
+21.68%
90d:
+106.38%
WAIT
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 24, 2026
Get Alerted When EMBC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: EMBC shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: EMBC shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$5.28
Based on 0.0% avg growth
INTRINSIC VALUE TODAY
$3.28
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 3.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: EMBC is currently trading at $6.79, which is considered extended relative to its 30-day fair value range of $5.39 to $6.27. From a valuation perspective, the stock is trading at a premium (Forward PE: 3.8) compared to its historical average (3.0). At these levels, the market is pricing in 8.4% annual earnings growth.
Technical Outlook: Technically, EMBC is in a strong uptrend. The price is approaching resistance at $6.74. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: EMBC scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. However, the stock is trading significantly above the average Wall Street target of $4.00. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, EMBC is in a strong uptrend. The price is approaching resistance at $6.74. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: EMBC scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. However, the stock is trading significantly above the average Wall Street target of $4.00. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$5.39 -
$6.27
Company Quality Score
35/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
17.6%
All Signals
- BEARISH: Price extended above range (+8.3% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BEARISH: Trading 40.1% above Wall St target ($4.00)
- BULLISH: Expecting earnings turnaround to 8.4% growth with -8.1% revenue growth
- WARNING: Composite score 35/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$5.39 -
$6.27
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$5.67
Resistance Level
$6.74
Current Trend
Strong Uptrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
3.79
Wall Street Target
$4.00
(-40.1%)
Revenue Growth (YoY)
-8.1%
Earnings Growth (YoY)
-53.7%
Profit Margin
8.6%
Valuation Premium vs History
+8.4% premium
PE vs Historical
3.8 vs 3.0
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+8.4%
(market-implied from PE analysis)
1-Year Target
$7.24
(+8%)
2-Year Target
$7.85
(+18%)
3-Year Target
$8.51
(+27%)
3-Yr Target (if PE normalizes)
(PE: 4→3)
PE COMPRESSION
$6.74
(+1%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: -4.0%)
$31.02
(+364%)
Base:
(SPY PE: 3.8, Growth: -4.0%)
$5.92
(-11%)
Bear:
(PE: 3.0, Growth: -4.0%)
$4.69
(-30%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (4x PE), but valuation improves significantly next year (4x PE) as earnings recover.
Trailing PE: 4.37 | Current EPS (TTM): $1.47
Bull Case
$8.47
(+27%)
Analyst growth 19.9%, PE expands to 4.8
Base Case
$7.70
(+15%)
Market implied 19.9%, PE stable at 4.4
Bear Case
$4.37
(-35%)
Severe decline -20.0%, PE contracts to 3.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 22, 2026 10:02 AM ET
Data refreshes hourly during market hours. Next update: 11:02 AM
Data refreshes hourly during market hours. Next update: 11:02 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EMBC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Instruments & Supplies Stocks
Top-rated stocks in Medical Instruments & Supplies by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ISRG
Intuitive Surgical Inc |
STRONG BUY
34 analysts |
$479 | 41 HOLD |
|
ALC
Alcon AG |
STRONG BUY
27 analysts |
$83 | 45 HOLD |
|
RGEN
Repligen Corporation |
STRONG BUY
22 analysts |
$198 | 53 HOLD |
|
WST
West Pharmaceutical Serv… |
STRONG BUY
17 analysts |
$413 | 37 SELL |
|
STVN
Stevanato Group SpA |
BUY
14 analysts |
$24 | 67 BUY |
